scholarly journals P14.21: Inter-observer agreement of uterine artery Doppler notching in a high-risk population

2014 ◽  
Vol 44 (S1) ◽  
pp. 266-267
Author(s):  
C. Mayer ◽  
J.A. Hutcheon ◽  
J. Robertson
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
Observer Agreement ◽  
High Risk Population ◽  
Risk Population ◽  
Uterine Artery Doppler

Second-trimester uterine artery Doppler, PlGF, sFlt-1, sEndoglin, and lipid-related markers for predicting preeclampsia in a high-risk population

2013 ◽  
Vol 33 (11) ◽  
pp. 1070-1074 ◽  
Author(s):  
Caroline Diguisto ◽  
Amélie Le Gouge ◽  
Eric Piver ◽  
Bruno Giraudeau ◽  
Franck Perrotin
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
High Risk Population ◽  
Second Trimester ◽  
Risk Population ◽  
Uterine Artery Doppler

CORRELATION OF ABNORMAL UTERINE ARTERY DOPPLER IN THE SECOND TRIMESTER OF PREGNANCY WITH MATERNAL AND FETAL OUTCOME.

2021 ◽  
pp. 18-19
Author(s):  
Sangeetha Menon ◽  
Jyotsna Nalinan
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
Subsequent Development ◽  
High Risk Population ◽  
Age Group ◽  
Second Trimester ◽  
Risk Population ◽  
Uterine Artery Doppler ◽  
Increased Risk ◽  
Doppler Indices

Introduction: Maternal – fetal circulation can be studied non-invasively by using doppler which can be used as a screening tool for fetal and maternal disease. Morphological changes in the uterine vasculature can be demonstrated by colour and pulsed doppler studies. The majority of the studies on uterine artery doppler have focused on a high risk population. The effectiveness of the uterine artery doppler to predict pre eclampsia or FGR in a low risk population has been shown to have a low to moderate predictive value1. Also the criteria for normal and abnormal uterine artery doppler continue to vary with no well accepted denition. Aim: To nd out the correlation between abnormal uterine artery doppler in the second trimester of pregnancy between 18-22 weeks, with the subsequent development of pre eclampsia and FGR. Materials and methods: This is a prospective cohort study carried out in the Department of Obstetrics and Gynecology for a period of one year. Antenatal patients in the age group of 18-35 years, between 18-22 weeks of gestation, who were included in the study underwent a uterine artery doppler. They were followed up until delivery. SPSS software was used to analyze the data. Results: 193 Obstetric patients in the age group 18-35 years were evaluated with uterine artery doppler. 77.7% had normal doppler indices. In the abnormal doppler group, 81.4% were in the high risk category and 48.8% of those with abnormal dopplers developed pre eclampsia and 34.9% with abnormal dopplers developed FGR. Conclusion: Patients with abnormal uterine artery doppler indices in the second trimester of pregnancy, had an 18 times increased risk of developing pre eclampsia and a 6 times increased risk of developing FGR when compared to those with normal doppler indices.

scholarly journals Role of pregnancy associated plasma protein-A and doppler velocimetry in the assessment of fetomaternal outcome in high risk pregnancy

2019 ◽  
Vol 8 (5) ◽  
pp. 1981
Author(s):  
Asmita Kaundal ◽  
Usha Gupta ◽  
Jayashree Bhattcharjee
Keyword(s):  
High Risk ◽  
Pregnancy Outcome ◽  
Plasma Protein ◽  
Uterine Artery ◽  
Protein A ◽  
High Risk Population ◽  
Risk Population ◽  
Uterine Artery Doppler ◽  
Adverse Pregnancy

Background: The study aimed at defining the role of Pregnancy associated plasma protein-A (PAPP-A) and uterine artery doppler (Ut.A.PI) in the development of adverse pregnancy outcome (APO) in high risk pregnancies.Methods: This was an observational study where 100 singleton pregnancies at high risk of development of APO, between 11 to 13 + 6 weeks POG were enrolled. PAPP-A levels were measured at 11 to 13 + 6 weeks POG and uterine artery doppler PI was measured at 20 weeks. Women were followed till delivery. Pregnancy outcome were seen and a cut off at which APO developed was derived.Results: In this study women with lower mean PAPP-A (0.75±0.19 MOM versus 1.23±0.31MOM) (p<0.001) values and higher Ut.A.PI (1.43±0.35MOM versus 0.99±0.25MOM) (p<0.001) developed APO. Cut off value for PAPP-A and Ut.A.PI was determined and was found to be ≤11.65 µg/ml (≤0.79MoM) and   >1.42 (>1.19MoM) respectively which was higher than what is determined in other studies done on low risks populations thereby suggesting for an intervention or more meticulous observations at a higher cut offs.Conclusions: PAPP-A and uterine artery doppler are already being used for the screening of preeclampsia in most of the countries but not for other adverse pregnancy outcomes. PAPP-A levels along with the uterine artery PI in predicting APO in high risk women has high negative predictive value. Hence can be uses as a screening method in high risk population whether they should be used for low risk population also needs further evaluation.

Second trimester angiotensing-converting enzyme and uterine artery Doppler as predictors of preeclampsia in a high-risk population

2015 ◽  
Vol 34 (2) ◽  
pp. 171-180 ◽  
Author(s):  
Ana Martínez-Ruiz ◽  
María Desamparados Sarabia-Meseguer ◽  
Juan Antonio Vílchez ◽  
Joaquín Pérez-Fornieles ◽  
Juan Luis Delgado-Marín ◽  
...  
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
High Risk Population ◽  
Converting Enzyme ◽  
Second Trimester ◽  
Risk Population ◽  
Uterine Artery Doppler

scholarly journals OP27.01: Uterine artery Doppler in a high risk population from Chile

2011 ◽  
Vol 38 (S1) ◽  
pp. 133-134
Author(s):  
M. Yamamoto ◽  
C. Jacobsen ◽  
M. De Alvarado ◽  
F. Jordan ◽  
L. Caicedo ◽  
...  
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
High Risk Population ◽  
Risk Population ◽  
Uterine Artery Doppler

First trimester uterine artery Doppler, sFlt-1 and PlGF to predict preeclampsia in a high-risk population

2017 ◽  
Vol 30 (13) ◽  
pp. 1514-1519 ◽  
Author(s):  
Caroline Diguisto ◽  
Eric Piver ◽  
Amélie Le Gouge ◽  
Florence Eboue ◽  
Claudine Le Vaillant ◽  
...  
Keyword(s):  
High Risk ◽  
Uterine Artery ◽  
First Trimester ◽  
High Risk Population ◽  
Risk Population ◽  
Uterine Artery Doppler

scholarly journals Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Maitri Kalra ◽  
Yan Tong ◽  
David R. Jones ◽  
Tom Walsh ◽  
Michael A. Danso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Neoadjuvant Therapy ◽  
Triple Negative ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Parp Inhibition ◽  
High Risk Population ◽  
Risk Population ◽  
The Impact

AbstractPatients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/BRCAmut) who had >2 cm of invasive disease in the breast or persistent lymph node (LN) involvement after neoadjuvant therapy were assigned 1:1 to cisplatin alone or with rucaparib. Germline mutations were identified with BROCA analysis. The primary endpoint was 2-year disease-free survival (DFS) with 80% power to detect an HR 0.5. From Feb 2010 to May 2013, 128 patients were enrolled. Median tumor size at surgery was 1.9 cm (0–11.5 cm) with 1 (0–38) involved LN; median Residual Cancer Burden (RCB) score was 2.6. Six patients had known deleterious BRCA1 or BRCA2 mutations at study entry, but BROCA identified deleterious mutations in 22% of patients with available samples. Toxicity was similar in both arms. Despite frequent dose reductions (21% of patients) and delays (43.8% of patients), 73% of patients completed planned cisplatin. Rucaparib exposure was limited with median concentration 275 (82–4694) ng/mL post-infusion on day 3. The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). In the high-risk post preoperative TNBC/BRCAmut setting, the addition of low-dose rucaparib did not improve 2-year DFS or increase the toxicity of cisplatin. Genetic testing was underutilized in this high-risk population.

Sign in / Sign up

Export Citation Format

Share Document